Related Experiment Video

Updated: Aug 10, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time

Ruben A Mesa, Heather Powell, Terra Lasho

    Haematologica
    |March 15, 2006
    PubMed

    Insights

    Serial analysis of the JAK2(V617F) mutation in myelofibrosis patients revealed stable mutation levels in most cases. Increases in JAK2 gene expression did not correlate with disease progression or transformation.

    Area of Science:

    • Hematology
    • Molecular Biology
    • Oncology

    Background:

    • Myelofibrosis with myeloid metaplasia is a myeloproliferative neoplasm.
    • The JAK2(V617F) mutation is a common driver mutation in myelofibrosis.
    • Monitoring mutation levels can provide insights into disease behavior.

    Purpose of the Study:

    • To assess the stability of the JAK2(V617F) mutation over time in myelofibrosis patients.
    • To investigate the relationship between JAK2 expression levels and disease progression.

    Main Methods:

    • Serial blood samples were collected from 44 myelofibrosis patients.
    • JAK2(V617F) mutation levels were analyzed over a median interval of 18.6 months.
    • JAK2 gene expression was also monitored.

    Main Results:

    • In 88% (22/25) of evaluable patients, no significant interval change in JAK2(V617F) mutation levels was observed.
    • Three patients showed an increase in JAK2 expression.
    • The observed increase in JAK2 expression did not correlate with disease progression or leukemic transformation.

    Conclusions:

    • The JAK2(V617F) mutation status is generally stable over time in myelofibrosis patients.
    • JAK2 gene expression levels may not be a reliable indicator of disease progression or transformation in this context.

    More Related Videos

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma15:07

    VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

    Published on: December 28, 2015

    Related Concept Videos

    Differentiation of Common Myeloid Progenitor Cells01:15

    Differentiation of Common Myeloid Progenitor Cells

    Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...